Revenue down 12%, PAT negative, but cost control and DEX contracts fuel medium-term conviction

Revenue -₹17.5 Cr YoY (~-12.5%); cost save ₹18 Cr (₹9.3 service + ₹8.7 overhead)

Reported OPM 13.6%, EBITDA margin up ~218 bps to 16.6%; YoY/QoQ growth credible but PAT -₹1.7 Cr due to depreciation +28%

DEX segment down 17% revenue, 4.3% EBITDA; one-time items total ~₹10.7 Cr; ₹34 Cr TCV announced with ₹22 Cr FY27 execution

Transcript shows both 3.8% and 7% figures; EBITDA growth 32–35% confirmed; Q1 seasonally light, Q2/Q3 peak

L&D revenue -15% (₹53→₹45 Cr); EBITDA -13%; OPM expansion +60 bps via cost control

₹34 Cr total contract value (₹22 Cr FY27 execution); prior call mentioned pipeline but no signed wins disclosed

Structural market churn ongoing; prior call expected 'continued pressure 2–4 quarters'; now in Q1 with -15% revenue

EBITDA +32–35% despite light Q1 and +3.8–7% revenue; margin leverage higher than expected

Salesforce, Dell, Infosys pilots now into deployment; previously communicated as 'pilots'; 45–50% FY27 growth target

Exams likely to consolidate to 3–4 from many (like JEE/NEET model). New opportunities will emerge; market size growing. DEXIT's robust tech + AI proctoring is a moat; few competitors meet new scrutiny thresholds.

BBA/IPM is a growth segment (5-yr MBA programs expanding). PhysicsWallah targets lower-end; CLE is middle-to-top. AI content now standard; quality and market reception matter most.

Multi-layer: on-desk tech proctoring, physical security, centralized NOC/SOC monitoring (like capital markets), AI captures iris/facial/sound, can shut down student session. Very few global competitors have this suite.

₹210 Cr loan → ₹174 Cr post-repayments. Goal: zero-debt in 36 months. Ongoing strategic discussions with global/Indian players for potential funding/M&A.

Per seat/per candidate basis. 60–65% govt tender (tech-commercial, CLE scores T1 but not always L1). 30–35% non-tender is steady, predictable, sustained revenue.

Launched 2–2.5 quarters back. Salesforce, Dell pilots → recurring activations. Infosys India pilot scaled to multiple divisions and APAC/US rollout. Singapore/US empanelment underway (90–150 days). Pilots with Deloitte, PwC, Elastic, AWS. Targeting 45–50% growth for VIRSA in FY27.

Management cites Q1 seasonal light; Q2/Q3 expected 'significantly heavier.' Segment-wise: DEX ₹22 Cr of ₹34 Cr TCV in FY27; VIRSA 45–50% growth.

Explicitly stated: 'will definitely continue to expand our EBITDA margin as compared to last year on a quarter-to-quarter basis.' Driven by ongoing cost rationalization from Q3 FY26 onwards.

60–70% of FY26–27 tech projects complete (exam engine, cyber/IT security, network expansion). Depreciation burden expected to continue impacting PAT short-term.

EdTech test prep revenue -15%; structural churn from AI-powered free resources (PhysicsWallah, free online platforms). Market consolidation ongoing. CLE's positioning (middle-to-top) may limit upside.

NEET fiasco and Nandan Nilekani task force creating policy uncertainty. Exam rationalization could consolidate market, favoring incumbents, but timing and scope unclear. NTA might develop in-house proctoring (though management confident CLE's tech is superior).

₹4.7 Cr DEX revenue pending finalization due to customer result delays. ₹6 Cr rollover from prior Q4 inflated Q1 FY26 baseline. These one-time items obscure true run-rate.

₹174 Cr debt remaining (down from ₹210 Cr); three-year zero-debt goal ambitious given PAT negative and capex ongoing. Debt repayment may compete with growth capex for MarTech/DEX expansion.

VIRSA is early-stage (launched 2–2.5 quarters back) and adoption-dependent. Singapore/US empanelment underway (90–150 days). 45–50% FY27 growth target aggressive if approvals slip into FY28.